KIFFIK Biomedical partners with Duracell & Rubix

Powering the Future of Diagnostics PHTA’s first resident, KIFFIK Biomedical, is changing the diagnostics landscape with a needle-free, interstitial fluid (ISF)-based diagnostic platform, the KIFFIK Lab™ – offering fast, accurate, and at-home disease detection. Now, through strategic partnerships with Duracell and Rubix, KIFFIK is accelerating the next generation of biomarker-driven diagnostics. These collaborations, supported by the PHTA ecosystem, are not just advancing cancer screening but also opening doors for broader industry innovation. “At KIFFIK, we believe that the future of diagnostics lies in harnessing the rich biomarker profile of interstitial …

Kiffik Biomedical & Rubix LS Partner To Revolutionize Cancer Diagnostics With Interstitial Fluid & Aptamer Technologies

[Providence, RI, 03/20/2025] – Kiffik Biomedical, a leader in interstitial fluid (ISF)-based diagnostics, has announced a strategic partnership with Rubix LS, a pioneer in aptamer-based precision medicine, to develop a first-of-its-kind rapid colorectal cancer test. This collaboration combines KIFFIK’s groundbreaking ISF biomarker collection technology with Rubix LS’s advanced aptamer detection platform, offering an innovative, non-invasive alternative to traditional screening methods. Colorectal cancer is one of the leading causes of cancer-related deaths worldwide, yet screening adherence remains low due to invasive procedures, discomfort, and stigma. By leveraging ISF-based biomarker detection and …

Global Partnership with Duracell Batteries to Power New, Innovative Health Monitoring Technology

Duracell® batteries will be integrated into KIFFIK Biomonitoring Devices, such as health monitors, that detect various biomarkers in the body. [Providence, RI, 01/29/2025] – KIFFIK Biomedical and Duracell U.S. Operations, Inc. (“Duracell”) have agreed to collaborate and assess the integration of long-lasting, efficient power solutions with cutting-edge biomonitoring technology. This is good news for patients and the public communities, as the partnership’s goal is to enhance the precision and dependability of health monitoring systems around the globe, ultimately benefitting users in hospitals, high-performance sports, the military, and at home with …
21Dec

December News

KIFFIK Biomedical secures a pivotal $50 million investment from GEM Global Yield, positioning the company as a ‘Unicorn-in-Waiting’ KIFFIK’s patented platform will disrupt current MedTech markets by offering real-time insights and personalized care in a way that was previously unimaginable while allowing healthcare professionals to fully diagnose, monitor, and more extensively treat patients remotely. Read More > “I’m excited to announce a major milestone for KIFFIK Biomedical. We want to thank our new partners GEM, as we continue to deliver on our mission of bringing promising new diagnostic advancements to …

Kiffik is on the verge of transforming the future of healthcare

The interstitial space is the primary source of lymph and is a major fluid compartment in the body. While the anatomy and composition of the interstitial space between cells is increasingly understood, the existence, location, and structure of larger inter- and intra-tissue spaces is described only vaguely in the literature.

The industry’s first noninvasive, remote point of care device that identifies biomarkers found in interstitial fluid

For the first time, extraction of bio-rich interstitial fluid (IF) with all its components will be available for multiple health applications. This addition to the medical professional’s toolkit opens the door to a range of opportunities. For scientists, physicians, veterinarians, and hospital professionals, there is the chance to perform continuous or periodic monitoring of critical biomarkers that are prevalent in diseases. The information learned from this fluid can help clinicians, researchers, and biopharmaceutical developers overcome the limitations of plasma and serum monitoring.